Kamada LtdKMDA
Price (close)
$8.83
Market cap
$509.4M
P/E
25.2x
Revenue (FY)
$180.5M
Net income
$20.2M
Dividend yield
4.76%
1-year total return
38.8%
Net margin
11.2%
Revenue growth
12.1%
Debt / equity
—
What Kamada Ltd does.
company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies
commercial portfolio, including continued investment in the commercialization and life cycle management of our Proprietary Products. Our
Proprietary Products consist of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, WINRHO SDF®,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $133.2M | $103.6M | $129.3M | $142.5M | $161.0M | $180.5M |
| Net income | $17.1M | -$2.2M | -$2.3M | $8.3M | $14.5M | $20.2M |
More on KMDA.
- Kamada Ltd summary
- Kamada Ltd financial statements
- Kamada Ltd key metrics
- Kamada Ltd health scores and style box
- Kamada Ltd earnings
- Kamada Ltd dividends
- Kamada Ltd valuation
- Kamada Ltd ownership and insiders
- Kamada Ltd peers
Figures from Kamada Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.